$22.68 Bn Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033
The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...
Managed Healthcare Executive2d
The Power of PBMs and Biosimilars, 2025 Launches of the Stelara Biosimilars, the IRA and Interchangeability | Q&A with Craig Burton, MBA
The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...
Managed Healthcare Executive3d
Health of the Biosimilars Industry, Getting Rid of Clinical Trials, PBMs As Obstacles and Other Biosimilar Topics | Q&A With Craig Burton, MBA
We spoke recently with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and lobbying group for the ...
Alvotech initiated with a Buy at UBS
UBS initiated coverage of Alvotech (ALVO) with a Buy rating and $18 price target Alvotech is a pure-play biosimilar company, with a ...
UBS downgrades Sandoz to 'neutral,' citing limited upside in Biosimilar growth
UBS forecasts that Sandoz will likely achieve the lower end of its 24-26% core EBITDA margin target by 2028. To reach the ...
AbbVie's SWOT analysis: stock outlook strong despite humira loss
AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...
pharmaphorum5d
AbbVie's Humira finally faces biosimilar challenge in US
AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after it was approved by the FDA.
Seeking Alpha29d
AbbVie keeps Humira lead as biosimilar entry nears two-year mark
However, according to Samsung Bioepis, ABBV continues to claim 72% of the adalimumab market in the U.S. as of November, even as its biosimilars have gained ground, claiming 23% of the market ...